Registered Nurse in Poinciana, FL Accepting Medicare
4 Registered Nurse nurses found. Showing 1 - 4
 Mrs. Olga L Aponte, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 105 N Doverplum, Poinciana, FL 34758 Phone: 407-943-8613 Fax: 407-943-8625 |
Nancy J Paolini, RN BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 105 N Doverplum Ave, Poinciana, FL 34758 Phone: 407-943-8616 Fax: 407-943-8625 |
Ms. Lisa Mcmillan, Registered Nurse - Administrator Medicare: Not Enrolled in Medicare Practice Location: 1661 Redfin Dr, Poinciana, FL 34759 Phone: 407-873-3662 Fax: 863-496-7260 |
Ivelisse Martinez-matos, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 105 N Doverplum Ave, Poinciana, FL 34758 Phone: 407-943-8600 Fax: 407-943-8625 |
News Archive
Nitric oxide released through nanotechnology may be a new way to treat, prevent acne
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that delays in the U.S. approval and launch of Theravance/Astellas's Vibativ (telavancin) for the treatment of nosocomial pneumonia will reduce by more than half the commercial impact that it was previously forecasted to garner in the methicillin-resistant Staphylococcus aureus (MRSA) drug market.
Lord Saatchi's Medical Innovation Bill may cause serious harm to patients
The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK's House of Lords "strikes at the heart of evidence-based medicine" and risks "opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine", according to a new Editorial published in The Lancet Oncology.
Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients
Isis Pharmaceuticals, Inc. announced today that it has initiated a study for ISIS-DMPK Rx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA.
› Verified 4 days ago